Artisan Partners Limited Partnership reduced its stake in shares of Novanta Inc. (NASDAQ:NOVT – Free Report) by 4.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 147,151 shares of the technology company’s stock after selling 6,361 shares during the quarter. Artisan Partners Limited Partnership owned 0.41% of Novanta worth $14,737,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds also recently added to or reduced their stakes in NOVT. Pilgrim Partners Asia Pte Ltd purchased a new stake in shares of Novanta during the 3rd quarter worth approximately $36,000. Migdal Insurance & Financial Holdings Ltd. acquired a new position in Novanta during the third quarter worth $40,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. purchased a new stake in Novanta during the second quarter worth $52,000. Huntington National Bank boosted its position in Novanta by 65.7% during the second quarter. Huntington National Bank now owns 492 shares of the technology company’s stock worth $63,000 after purchasing an additional 195 shares in the last quarter. Finally, Harbor Investment Advisory LLC grew its holdings in Novanta by 47.1% in the third quarter. Harbor Investment Advisory LLC now owns 987 shares of the technology company’s stock valued at $99,000 after purchasing an additional 316 shares during the last quarter. 98.35% of the stock is owned by hedge funds and other institutional investors.
Insider Activity at Novanta
In other Novanta news, CEO Matthijs Glastra sold 7,500 shares of the stock in a transaction on Tuesday, February 10th. The stock was sold at an average price of $145.04, for a total transaction of $1,087,800.00. Following the transaction, the chief executive officer owned 57,367 shares of the company’s stock, valued at $8,320,509.68. This represents a 11.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Robert Buckley sold 1,423 shares of the firm’s stock in a transaction on Friday, February 20th. The stock was sold at an average price of $140.88, for a total value of $200,472.24. Following the sale, the chief financial officer owned 93,814 shares in the company, valued at $13,216,516.32. This trade represents a 1.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 24,346 shares of company stock worth $3,382,737 in the last three months. Insiders own 1.20% of the company’s stock.
Analyst Upgrades and Downgrades
Read Our Latest Analysis on NOVT
Novanta Stock Down 1.6%
NOVT opened at $134.43 on Friday. The company has a quick ratio of 1.54, a current ratio of 3.69 and a debt-to-equity ratio of 0.16. The firm has a market cap of $4.80 billion, a P/E ratio of 92.08 and a beta of 1.62. Novanta Inc. has a 52 week low of $98.27 and a 52 week high of $149.95. The business’s fifty day simple moving average is $133.34 and its 200 day simple moving average is $120.38.
Novanta (NASDAQ:NOVT – Get Free Report) last announced its earnings results on Monday, February 23rd. The technology company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.03. The firm had revenue of $258.35 million during the quarter, compared to the consensus estimate of $260.72 million. Novanta had a net margin of 5.49% and a return on equity of 13.12%. During the same quarter in the previous year, the company posted $0.76 EPS. Novanta has set its FY 2026 guidance at 3.500-3.650 EPS and its Q1 2026 guidance at 0.750-0.800 EPS. As a group, equities research analysts anticipate that Novanta Inc. will post 3.03 EPS for the current fiscal year.
About Novanta
Novanta, Inc (NASDAQ: NOVT) is a global technology company that designs and manufactures precision components, subsystems and software used in advanced photonics and motion control applications. The company serves customers in the medical device and advanced industrial markets, supplying critical technologies for diagnostics and therapeutic systems, semiconductor and electronics manufacturing, and scientific instrumentation. Novanta’s product portfolio includes laser control modules, optics, beam delivery systems, high-precision motors, actuators, stages, and fluidics solutions designed to meet stringent accuracy and reliability requirements.
Novanta’s Photonics segment delivers laser and energy delivery components that enable minimally invasive surgical procedures and diagnostic imaging.
See Also
- Five stocks we like better than Novanta
- The gold chart Wall Street is terrified of…
- This makes me furious
- America’s 1776 happening again
- Buy this Gold Stock Before May 2026
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
Want to see what other hedge funds are holding NOVT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novanta Inc. (NASDAQ:NOVT – Free Report).
Receive News & Ratings for Novanta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novanta and related companies with MarketBeat.com's FREE daily email newsletter.
